Home Investors Contact The business of NORDA ASA (former NorDiag ASA) is research and development, and to offer services and products within the biotechnology sector, including participating in other companies with similar operations, as well as trading with and investing in securities, real estates and other assets. The Company has May 4, 2012 sold its sample preparation business to DiaSorin. Going forward NORDA ASA will focus on the development of the Colorectal Cancer diagnostic screening test Genefec™. General Meeting 2021, Minutes Download/Read Document Read more about General Meeting 2021, Minutes Innkalling til ordinær generalforsamling 29. juni 2021 Innkalling til OGM 2021 Read more about Innkalling til ordinær generalforsamling 29. juni 2021 NORDA ASA. Årsrapport 2020 Norda Årsapport 2020 Read more about NORDA ASA. Årsrapport 2020 News archive NORDA ASA ♦ Stortingsgaten 28 ♦ 0161 Oslo ♦ Norway ♦ Phone: +47 924 23 561 ♦ web: www.nordasa.no

Home Investors Contact You are here Home » Investors Reports & Presentations English Norwegian Date --- Norda Årsrapport 2020 Revisjonsberetning 2020 Norda 21 June 2021 --- 2020 - Norda Mellombalanse per 31.10.20 2020 - Revisorsberetning mellombalanse 18 November 2020 --- 2019 - Årsrapport 2019 2019 - Revisjonsberetning 25 June 2020 --- 2018 21 June 2019 --- 2017 14 June 2018 --- 2016 22 June 2017 --- 2015 28 May 2016 --- 2014 28 May 2015 --- 2013 30 May 2014 2012 --- 09 April 2013 NORDA ASA ♦ Stortingsgaten 28 ♦ 0161 Oslo ♦ Norway ♦ Phone: +47 924 23 561 ♦ web: www.nordasa.no